Transcatheter Aortic Valve Replacement (TAVR)

TAVR is recommended for patients with symptomatic severe aortic stenosis (valve area <1.0 cm², mean gradient >40 mmHg). According to ACC/AHA guidelines, TAVR is strongly recommended for patients age 80+ when transfemoral access is suitable, and offered as a shared decision with the Heart Team for ages 65-80. Patients under 65 generally favor surgical AVR due to longer-term durability data, though TAVR may be considered case-by-case. Factors favoring TAVR include prior cardiac surgery, chest radiation, severe COPD, liver cirrhosis, porcelain aorta, and patient preference for a less invasive approach.

Published clinical trial data shows comparable outcomes between TAVR and SAVR in low-risk patients through 7 years of follow-up. PARTNER 3 at 7 years reported all-cause mortality of 19.5% for TAVR vs 16.8% for SAVR with no statistically significant difference. TAVR demonstrates significantly lower rates of new atrial fibrillation (17.7% vs 43.5%), faster recovery, and shorter hospital stays, while SAVR may offer advantages in valve durability data beyond 10 years. A 2025 meta-analysis of 6 RCTs (5,341 patients) showed a 20% reduction in all-cause death at 5 years with TAVR.

Two main platforms are available: Edwards SAPIEN 3/Ultra (balloon-expandable, bovine pericardial tissue, sizes 20-29mm) and Medtronic Evolut PRO+/FX (self-expanding nitinol frame, porcine pericardial tissue, sizes 23-34mm). SAPIEN offers lower pacemaker rates (8-12%) but cannot be repositioned once deployed. Evolut provides repositionability and a larger size range but has higher pacemaker rates (15-27%). Both are available at major Thai cardiac centers. Your Heart Team will recommend the optimal device based on your anatomy.

Recovery is significantly faster than open surgery. Most transfemoral patients walk within 12-24 hours and are discharged in 1-3 days. Driving resumes at 2 weeks, light exercise and sedentary work at 2-3 weeks, and full activities including golf, tennis, and swimming at 6-8 weeks. Maximum hemodynamic benefit occurs at 3-6 months with quality of life improvements reported as sustained 5+ years in published studies.

General guidelines suggest waiting 7-14 days after a transfemoral TAVR (14-21 days for non-transfemoral approaches) before flying. For long-haul flights, published recommendations include compression stockings, adequate hydration, an aisle seat for walking every 1-2 hours, and consideration of DVT prophylaxis for flights exceeding 8 hours. Altitude above 2,500m should be avoided for 4 weeks. Your treating physician will assess individual fitness-to-fly based on your specific recovery.

Thailand's TAVR packages at accredited hospitals typically range from $30,000-$85,000, compared to estimated US hospital charges of $100,000-$200,000. Estimated savings are approximately 55-70%. Thailand's packages generally include pre-operative diagnostics, Heart Team consultation, the valve device ($20,000-$40,000 alone), catheterization lab, ICU monitoring, hospitalization, and follow-up echocardiography. The valve device represents 45-60% of total cost and is priced similarly worldwide. Actual costs depend on valve type, approach, complications, and individual factors.

New permanent pacemaker implantation occurs in 8-27% of TAVR patients, depending primarily on valve type. Balloon-expandable valves (Edwards SAPIEN) have lower rates of 8-12%, while self-expanding valves (Medtronic Evolut) range from 15-27% due to deeper implantation in the left ventricular outflow tract. Pre-existing conduction abnormalities (right bundle branch block) increase risk. Your Heart Team will discuss pacemaker risk based on your anatomy and the recommended valve type.

Published 5-year data shows 93-96% freedom from structural valve deterioration. The PARTNER 3 trial reported bioprosthetic valve failure of 6.9% for TAVR versus 7.3% for surgical valves at 7 years, with no significant difference. Emerging 10-year data from earlier high-risk cohorts suggests approximately 85% durability, though these patients had different risk profiles. When structural deterioration occurs, valve-in-valve TAVR is feasible, avoiding repeat open surgery. Annual echocardiographic surveillance is recommended lifelong.

Plan for a minimum 2-3 week stay: 3-5 days for pre-operative workup (CT angiography, echocardiogram, coronary assessment, Heart Team conference), 1-5 days for the procedure and hospital recovery, and 10-14 days for post-procedure monitoring before fitness-to-fly clearance. Most complications present in the first week. A 30-day echocardiogram (new baseline for valve surveillance) is ideally performed at the treating center before departure. Thai cardiac centers offer telemedicine follow-up for international patients.

Cerebral embolic protection devices (such as the Sentinel system) can be deployed during TAVR to capture calcific debris before it reaches the brain. Published data demonstrates reduction in measurable cerebral embolic lesions, though clinical stroke benefit remains under investigation. Not all centers use cerebral protection routinely — discuss availability with your Heart Team. Additional stroke prevention includes careful patient selection, CT-based planning to minimize valve manipulation, and antiplatelet therapy.

Essential studies include ECG-gated CT angiography (the most critical study for annular sizing and access planning), transthoracic echocardiogram (confirming AS severity and LV function), and coronary angiography (25-50% of severe AS patients have significant concurrent coronary disease). Additional assessments may include pulmonary function tests, carotid duplex ultrasound, frailty assessment, and mandatory dental clearance to prevent prosthetic valve endocarditis. Your Heart Team uses these results to determine valve type, size, and approach.